BioOutsource preparing for biosimilars boom
Scotland, UK-based vaccine and microbiological testing company BioOutsource today announced a major initiative in new R&D programs to support the next generation of biosimilars.
“We are proud to have established a reputation as one of the top providers in comparability of biosimilars,” commented BioOutsource chief executive Gerry MacKay. “With global biosimilar sales last year of $1.3 billion expected to explode to $35 billion by 2020, now is the time to leverage our base of knowledge and dramatically expand our R&D efforts to support the next generation of biosimilars. This investment will benefit both new and existing clients and enable them to ride the biosimilars wave with us,” he pointed out.
Next-generation biosimilars include Stelara, Yervoy, Orencia, Synagis and Actemra
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze